Abstract
Endovascular (EVAR) abdominal aortic aneurysm (AAA) repair has been established as a successful procedure in the short term and may constitute a viable long-term alternative to open repair (OR). The procedure has been associated with lower operative and mid-term morbidity and mortality compared to OR, but long-term results remain largely controversial. EVAR has also been associated with a significant risk of implant and procedure-related complications, such as graft thrombosis and cardiovascular events, necessitating interventional and pharmaceutical management. Medical management of patients undergoing EVAR is required for several different reasons. Patients with an AAA have an increased risk of cardiovascular death, necessitating treatment to reduce the overall risk for cardiovascular events. Treatment is inline with the medical management of coronary artery disease including anti-platelet therapy and statins. Anti-platelet therapy is also mandatory to prevent complications such as graft-limb thrombosis and peripheral arterial disease (PAD), which is common in patients with an AAA. Especially in patients with PAD, aspirin, clopidogrel and statins remain the mainstay of medical management. Unfortunately, there is a lack of prospective randomised trials concerning the medical management of patients that have undergone abdominal aortic endo-grafting. We review the current literature on the medical treatment of patients undergoing EVAR, focusing on peri-operative management, anti-platelet agents and statins.
Keywords: Endovascular, abdominal aortic aneurysm, pharmacotherapy
Current Vascular Pharmacology
Title: Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Volume: 6 Issue: 4
Author(s): Athanasios Saratzis, Nikolaos Saratzis, Nikolaos Melas and Dimitrios Kiskinis
Affiliation:
Keywords: Endovascular, abdominal aortic aneurysm, pharmacotherapy
Abstract: Endovascular (EVAR) abdominal aortic aneurysm (AAA) repair has been established as a successful procedure in the short term and may constitute a viable long-term alternative to open repair (OR). The procedure has been associated with lower operative and mid-term morbidity and mortality compared to OR, but long-term results remain largely controversial. EVAR has also been associated with a significant risk of implant and procedure-related complications, such as graft thrombosis and cardiovascular events, necessitating interventional and pharmaceutical management. Medical management of patients undergoing EVAR is required for several different reasons. Patients with an AAA have an increased risk of cardiovascular death, necessitating treatment to reduce the overall risk for cardiovascular events. Treatment is inline with the medical management of coronary artery disease including anti-platelet therapy and statins. Anti-platelet therapy is also mandatory to prevent complications such as graft-limb thrombosis and peripheral arterial disease (PAD), which is common in patients with an AAA. Especially in patients with PAD, aspirin, clopidogrel and statins remain the mainstay of medical management. Unfortunately, there is a lack of prospective randomised trials concerning the medical management of patients that have undergone abdominal aortic endo-grafting. We review the current literature on the medical treatment of patients undergoing EVAR, focusing on peri-operative management, anti-platelet agents and statins.
Export Options
About this article
Cite this article as:
Saratzis Athanasios, Saratzis Nikolaos, Melas Nikolaos and Kiskinis Dimitrios, Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms, Current Vascular Pharmacology 2008; 6 (4) . https://dx.doi.org/10.2174/157016108785909689
DOI https://dx.doi.org/10.2174/157016108785909689 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Overview of the Design, Development and Applications of Biodegradable Stents
Drug Delivery Letters Recent Patents on Electrospun Biomedical Nanostructures: An Overview
Recent Patents on Biomedical Engineering (Discontinued) Safety of Drug Eluting Stents: Current Concerns and Controversies
Current Drug Safety Current Approach to the Diagnosis and Treatment of Femoral-Popliteal Arterial Disease. A Systematic Review
Current Cardiology Reviews The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Prophylactic Neuroprotection
Current Drug Targets Genetics of Atherosclerosis in Murine Models
Current Drug Targets Context-Dependent Regulation of Nrf2/ARE Axis on Vascular Cell Function during Hyperglycemic Condition
Current Diabetes Reviews Magnetic Resonance Imaging of Iron in Parkinsons Disease
Current Medical Imaging Diabetic CVD – Soluble Epoxide Hydrolase as A Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality
Current Diabetes Reviews Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry The Role of Pericytes in Neurovascular Unit: Emphasis on Stroke
Current Drug Targets Myocardial Infarction Following Atherosclerosis in Murine Models
Current Drug Targets Signaling Through Rho GTPase Pathway as Viable Drug Target
Current Medicinal Chemistry Nifedipine Inhibits the Progression of An Experimentally Induced Cerebral Aneurysm in Rats with Associated Down-Regulation of NF-Kappa B Transcriptional Activity
Current Neurovascular Research A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology